SARDOMOZIDE DIHYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H14N6.2ClH
Molecular Weight	303.191
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure of SARDOMOZIDE DIHYDROCHLORIDE

Structure Search

SMILES

Cl.Cl.NC(=N)N\N=C1/CCC2=C(C=CC=C12)C(N)=N

InChI

InChIKey=UHEIPGJSFDAPIC-NENXIMLWSA-N

InChI=1S/C11H14N6.2ClH/c12-10(13)8-3-1-2-7-6(8)4-5-9(7)16-17-11(14)15;;/h1-3H,4-5H2,(H3,12,13)(H4,14,15,17);2*1H/b16-9+;;

HIDE SMILES / InChI

Molecular Formula	C11H14N6
Molecular Weight	230.2691
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9078276 | https://www.ncbi.nlm.nih.gov/pubmed/14977828 | https://adisinsight.springer.com/drugs/800004127

Sardomozide (previously known as SAM486A or CGP-48664) was developed as an inhibitor of S-adenosyl-methionine-decarboxylase, a key enzyme for polyamine biosynthesis. Sardomozide possessed the broad-spectrum antiproliferative and antitumor activity. The drug participated in a phase II clinical trial as a monotherapy in patients with refractory or relapsed non-Hodgkin's lymphoma. In Phase II clinical trial in patients with metastatic melanoma, the drug didn’t have significant therapeutic potential. The further development of this drug was discontinued.

Originator

Approval Year

C_max

Value	Dose	Analyte	Population
97.8 ng/mL EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	3.6 mg/m² 1 times / day steady-state, intravenous dose: 3.6 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
100 ng/mL EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	7.2 mg/m² 1 times / day steady-state, intravenous dose: 7.2 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
341 ng/mL EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	14.4 mg/m² 1 times / day steady-state, intravenous dose: 14.4 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
443 ng/mL EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	21.6 mg/m² 1 times / day steady-state, intravenous dose: 21.6 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
277 ng/mL EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	28.8 mg/m² 1 times / day steady-state, intravenous dose: 28.8 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2580 ng/mL EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	38.4 mg/m² 1 times / day steady-state, intravenous dose: 38.4 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
880 ng/mL EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	51.2 mg/m² 1 times / day steady-state, intravenous dose: 51.2 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2470 ng/mL EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	102.4 mg/m² 1 times / day steady-state, intravenous dose: 102.4 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6160 ng/mL EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	150 mg/m² 1 times / day steady-state, intravenous dose: 150 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7450 ng/mL EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	202.8 mg/m² 1 times / day steady-state, intravenous dose: 202.8 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
956 ng × h/mL EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	3.6 mg/m² 1 times / day steady-state, intravenous dose: 3.6 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1460 ng × h/mL EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	7.2 mg/m² 1 times / day steady-state, intravenous dose: 7.2 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4350 ng × h/mL EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	14.4 mg/m² 1 times / day steady-state, intravenous dose: 14.4 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10600 ng × h/mL EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	21.6 mg/m² 1 times / day steady-state, intravenous dose: 21.6 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1190 ng × h/mL EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	28.8 mg/m² 1 times / day steady-state, intravenous dose: 28.8 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11600 ng × h/mL EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	38.4 mg/m² 1 times / day steady-state, intravenous dose: 38.4 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
20900 ng × h/mL EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	51.2 mg/m² 1 times / day steady-state, intravenous dose: 51.2 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
39200 ng × h/mL EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	102.4 mg/m² 1 times / day steady-state, intravenous dose: 102.4 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
67800 ng × h/mL EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	150 mg/m² 1 times / day steady-state, intravenous dose: 150 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
73000 ng × h/mL EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	202.8 mg/m² 1 times / day steady-state, intravenous dose: 202.8 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
18.5 h EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	3.6 mg/m² 1 times / day steady-state, intravenous dose: 3.6 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
51.3 h EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	7.2 mg/m² 1 times / day steady-state, intravenous dose: 7.2 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
50.7 h EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	14.4 mg/m² 1 times / day steady-state, intravenous dose: 14.4 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
239 h EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	21.6 mg/m² 1 times / day steady-state, intravenous dose: 21.6 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
14.2 h EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	28.8 mg/m² 1 times / day steady-state, intravenous dose: 28.8 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
44.8 h EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	38.4 mg/m² 1 times / day steady-state, intravenous dose: 38.4 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
165 h EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	51.2 mg/m² 1 times / day steady-state, intravenous dose: 51.2 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
62.2 h EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	102.4 mg/m² 1 times / day steady-state, intravenous dose: 102.4 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
45.5 h EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	150 mg/m² 1 times / day steady-state, intravenous dose: 150 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
78.5 h EXPERIMENT https://aacrjournals.org/clincancerres/article/8/7/2157/289121/A-Phase-I-and-Pharmacokinetic-Study-of-SAM486A-a	202.8 mg/m² 1 times / day steady-state, intravenous dose: 202.8 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SARDOMOZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

PubMed

Title	Date	PubMed
Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma.	2009-07	19584241
Inhibition of multidrug-resistant HIV-1 by interference with cellular S-adenosylmethionine decarboxylase activity.	2006-09-15	16941339
CGP 48664, a potent and specific S-adenosylmethionine decarboxylase inhibitor: effects on regulation and stability of the enzyme.	1997-02-15	9078276
4-Amidinoindan-1-one 2'-amidinohydrazone: a new potent and selective inhibitor of S-Adenosylmethionine decarboxylase.	1993-07-23	8340919

Patents

Sample Use Guides

In Vivo Use Guide

Forty-one previously treated patients with either diffuse large cell, follicular, or peripheral T-cell NHL were treated i.v. with 100 mg/m(2) SAM486A (SARDOMOZIDE) as a daily 1-h infusion for 5 days repeated every 3 weeks. Treatment was continued for a total of eight cycles or until disease progression.

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Mon Mar 31 23:14:32 GMT 2025` Edited by `admin` on `Mon Mar 31 23:14:32 GMT 2025`
Record UNII	OEH39O5H7C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CGP 48664A

Preferred Name

English

SARDOMOZIDE DIHYDROCHLORIDE

Common Name

English

HYDRAZINECARBOXIMIDAMIDE, 2-(4-(AMINOIMINOMETHYL)-2,3-DIHYDRO-1H-INDEN-1-YLIDENE)-, HYDROCHLORIDE (1:2)

Systematic Name

English

CGP-48664A

Code

English

Code System Code Type Description

FDA UNII

OEH39O5H7C

Created by admin on Mon Mar 31 23:14:32 GMT 2025 , Edited by admin on Mon Mar 31 23:14:32 GMT 2025

PRIMARY

PUBCHEM

10402702

Created by admin on Mon Mar 31 23:14:32 GMT 2025 , Edited by admin on Mon Mar 31 23:14:32 GMT 2025

PRIMARY

CAS

138794-73-7

Created by admin on Mon Mar 31 23:14:32 GMT 2025 , Edited by admin on Mon Mar 31 23:14:32 GMT 2025

PRIMARY

Related Record Type Details


					CEB05S0B9I

SARDOMOZIDE

PARENT -> SALT/SOLVATE

Related Record Type Details


					CEB05S0B9I

SARDOMOZIDE

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/9078276 | https://www.ncbi.nlm.nih.gov/pubmed/14977828 | https://adisinsight.springer.com/drugs/800004127

Originator

Approval Year

Cmax

AUC

T1/2

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9078276 | https://www.ncbi.nlm.nih.gov/pubmed/14977828 | https://adisinsight.springer.com/drugs/800004127

C_max

T_1/2